Features | Partner Sites | Information | LinkXpress
Sign In
JIB
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING

Experimental Drug Reverses Cognitive Impairment in Aged Alzheimer's Disease Mice

By BiotechDaily International staff writers
Posted on 29 May 2013
Image: Senior author Dr. Dave Schubert (Photo courtesy of the Salk Institute for Biological Studies).
Image: Senior author Dr. Dave Schubert (Photo courtesy of the Salk Institute for Biological Studies).
Image: First author Dr. Marguerite Prior holding ampoule of the J147 drug (Photo courtesy of the Salk Institute for Biological Studies).
Image: First author Dr. Marguerite Prior holding ampoule of the J147 drug (Photo courtesy of the Salk Institute for Biological Studies).
Image: Salk Institute scientists developed J147, a synthetic drug shown to improve memory and prevent brain damage in mice with Alzheimer's disease (Photo courtesy of the Salk Institute for Biological Studies).
Image: Salk Institute scientists developed J147, a synthetic drug shown to improve memory and prevent brain damage in mice with Alzheimer's disease (Photo courtesy of the Salk Institute for Biological Studies).
An experimental drug for treatment of Alzheimer's disease (AD) gave excellent results in a mouse model of the disease and is expected to be tested in clinical trials leading to its eventual use in humans.

The drug, J147, is an orally bioavailable, blood brain-barrier permeable benzylidine-acetohydrazide compound proven safe in mice that was developed by researchers at the Salk Institute for Biological Studies (La Jolla, CA, USA). The potential of J147 for treatment of AD was discovered during a screening process using cultured neurons, a system that mimicked the brain of a patient with advanced AD.

In the current study, Salk Institute investigators treated aged AD mice with J147. Cognitive behavioral assays, histology, ELISA, and Western blotting were used to assay the effect of J147 on memory, amyloid metabolism, and neuroprotective pathways. J147 was also investigated in a scopolamine-induced model of memory impairment and compared to the drug donepezil, the most widely prescribed compound for treatment of AD.

Results published in the May 14, 2013, online edition of the journal Alzheimer's Research and Therapy revealed that J147 had the ability to rescue cognitive deficits when administered at a late stage in the disease. The ability of J147 to improve memory in aged AD mice was correlated with its induction of the neurotrophic factors NGF (nerve growth factor) and BDNF (brain derived neurotrophic factor) as well as several BDNF-responsive proteins that are important for learning and memory.

The comparison between J147 and donepezil in the scopolamine model showed that while both compounds were comparable at rescuing short term memory, J147 was superior at rescuing spatial memory and a combination of the two worked best for contextual and cued memory.

"Alzheimer's disease research has traditionally focused on a single target, the amyloid pathway," said senior author Dr. Dave Schubert, professor of cellular neurobiology at the Salk Institute for Biological Studies, "but unfortunately drugs that have been developed through this pathway have not been successful in clinical trials. Our approach is based on the pathologies associated with old age - the greatest risk factor for Alzheimer's and other neurodegenerative diseases - rather than only the specificities of the disease."

"In addition to yielding an exceptionally promising therapeutic, both the strategy of using mice with existing disease and the drug discovery process based upon aging are what make the study interesting and exciting," said Dr. Schubert, "because it more closely resembles what happens in humans, who have advanced pathology when diagnosis occurs and treatment begins. Most studies test drugs before pathology is present, which is preventive rather than therapeutic and may be the reason drugs do not transfer from animal studies to humans."

Related Links:

Salk Institute for Biological Studies




comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: Alternative splicing produces two protein isoforms (Photo courtesy of Wikimedia Commons).

Key Regulator of Cancer-Inducing Alternative Splicing Identified

Cancer researchers have identified the splicing factor RBM4 (RNA-binding protein 4) as a key determinant in processes that prevent tumor development and spread. RBM4 is known to be crucial to gene splicing... Read more

Therapeutics

view channel
Image: Hair follicle (blue) being attacked by T cells (green) (Photo courtesy of Christiano Lab/Columbia University Medical Center).

Hair Restoration Method Clones Patients’ Cells to Grow New Hair Follicles

Researchers have developed of a new hair restoration approach that uses a patient’s cells to grow new hair follicles. In addition, the [US] Food and Drugs Administration (FDA) recently approved a new drug... Read more

Lab Technologies

view channel
Image: Leica Microsystems launches the inverted research microscope platform Leica DMi8 (Photo courtesy of Leica Microsystems).

New Inverted Microscope Designed to Readily Adapt to Changing Research Demands

A new inverted microscope for biotech and other life science laboratories was designed to readily accommodate modifications and upgrades to allow it to keep current with changing research demands and interests.... Read more

Business

view channel

Partnership Established to Decode Bowel Disease

23andMe (Mountain View, CA,USA), a personal genetics company, is collaborating with Pfizer, Inc. (New York, NY, USA), in which the companies will seek to enroll 10,000 people with inflammatory bowel disease (IBD) in a research project designed to explore the genetic factors associated with the onset, progression, severity,... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.